Compare INTG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTG | GANX |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.7M | 76.8M |
| IPO Year | 1995 | 2021 |
| Metric | INTG | GANX |
|---|---|---|
| Price | $28.40 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 51.9K | ★ 437.7K |
| Earning Date | 09-28-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $74,753,000.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.66 | ★ N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $19.29 | $1.53 |
| 52 Week High | $52.00 | $4.34 |
| Indicator | INTG | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 30.94 | 43.61 |
| Support Level | $28.51 | $1.71 |
| Resistance Level | $32.82 | $1.85 |
| Average True Range (ATR) | 2.18 | 0.10 |
| MACD | -1.04 | -0.01 |
| Stochastic Oscillator | 6.56 | 31.07 |
The Intergroup Corp is a company operating in the real estate sector. It was formed to buy, develop, operate, rehabilitate, and dispose of real property of various types and descriptions, as well as to engage in other related business and investment activities. The company operates through three segments: Hotel, Real Estate, and Investment Transactions. The Hotel Operations segment, which generates the majority of the revenue, covers the operation of the Hilton hotel and garage. The Real Estate Operations segment involves the management of multifamily rental properties, while the Investment Transactions segment includes investments of cash in marketable securities and other assets.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.